Related Experiment Videos

Effects of digoxin on chemoreflex in patients with chronic heart failure

F Paganelli1, J M Maixent, R Gélisse

  • 1Service de Cardiologie, H pital Nord Marseille, CHU Nord, Chemin des Bourrelly, Marseille, France. Fpaganelli@mail.ap-hm.fr

Insights

Digoxin therapy in chronic heart failure patients improved hemodynamic function and blood gas levels. This treatment appeared to inactivate the chemoreflex, suggesting a potential new therapeutic avenue for heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Digitalis effects on baroreflexes in heart failure are known.
  • Chemoregulation remains functional in cardiac failure.
  • The impact of digoxin on chemoreflexes requires investigation.

Purpose of the Study:

  • To evaluate chronic digoxin administration effects on chemoreflexes in chronic heart failure.
  • To assess changes in hemodynamic and blood gas parameters.
  • To determine if digoxin alters chemoreflex activation.

Main Methods:

  • Assessed hemodynamic and blood gas parameters in 7 chronic congestive heart failure patients.
  • Administered digoxin (0.25 mg daily) for 10 days.
  • Measured parameters at baseline and after 30 min of pure O2 inhalation to inhibit chemoreflexes.

Main Results:

  • Digoxin therapy increased cardiac output, stroke volume, and PaO2.
  • Digoxin therapy decreased heart rate, systemic resistance, and pulmonary wedge pressure.
  • Post-digoxin, O2 inhalation did not alter heart rate or hemodynamics, indicating chemoreflex inactivation.

Conclusions:

  • Chronic digoxin therapy appears to inactivate the chemoreflex in heart failure patients.
  • This inactivation may stem from digoxin's sympatho-inhibitory and positive inotropic effects.
  • Improved hemodynamics and blood gases likely contribute to reflex inactivation.

Related Concept Videos